Dipasquale V, Gramaglia S M C, Catena M A, Romano C
Unit of Pediatrics, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy.
J Clin Pharm Ther. 2018 Feb;43(1):107-109. doi: 10.1111/jcpt.12586. Epub 2017 Jun 23.
Infliximab is a widely used drug for treating inflammatory bowel disease (IBD). This drug is known to rarely cause pericarditis in adult populations.
This report details the case of a 14-year-old boy with ulcerative colitis who developed pericarditis after a second infliximab infusion. After discontinuation of therapy, the patient's symptoms were resolved.
To our knowledge, this is the first reported paediatric case of pericarditis as a possible complication of infliximab therapy in IBD. Among infliximab-related delayed adverse reactions, cardiac complications should be monitored in the paediatric population.
英夫利昔单抗是一种广泛用于治疗炎症性肠病(IBD)的药物。已知该药物在成人中很少引起心包炎。
本报告详细介绍了一名14岁溃疡性结肠炎男孩在第二次输注英夫利昔单抗后发生心包炎的病例。停药后,患者症状缓解。
据我们所知,这是首例报告的英夫利昔单抗治疗IBD可能并发心包炎的儿科病例。在英夫利昔单抗相关的延迟不良反应中,应监测儿科患者的心脏并发症。